Literature DB >> 30637281

Informant- and Self-Appraisals on the Psychosis and Hallucinations Questionnaire (PsycH-Q) Enhances Detection of Visual Hallucinations in Parkinson's Disease.

Alana J Muller1, Joanna M Z Mills1,2, Claire O'Callaghan1,3,4,5, Sharon L Naismith1,6, Paul D Clouston1, Simon J G Lewis1, James M Shine1,7.   

Abstract

BACKGROUND: Clinicians vary in their ability to elicit and interpret hallucinatory symptoms in patients with Parkinson's disease (PD). There is limited evidence for informant-report measures of PD hallucinations as adjuncts to clinician-rated scales.
OBJECTIVES: To determine the utility of an informant version of the validated Psychosis and Hallucinations Questionnaire (PsycH-Q) for assessing the presence and severity of hallucinations in PD; and, to evaluate accuracy of clinician judgements by comparison with informant report and self-report.
METHODS: One hundred sixty-three PD patient-informant dyads completed self- and informant-report versions of PsycH-Q and three common questionnaire measures: Neuropsychiatric Inventory Questionnaire; Parkinson's Psychosis Questionnaire; and Scales for Outcomes in Parkinson's disease-Psychiatric Complications. We compared self-ratings and informant ratings across analogous subscales for the presence of hallucinations with clinician interview ratings on MDS-UPDRS as a diagnostic standard.
RESULTS: There was a low level of agreement between dyads (average κ = 0.39; κ range = 0.32-0.47; P < 0.001), and patients indicated the highest prevalence of hallucinations compared to informant or clinician estimates. Clinician interview missed 32% of PsycH-Q hallucinators identified by dyads. Relative to the sample, 22 patients with exclusively clinician-appraised hallucinations had poorer overall quality of life measured by the Parkinson's Disease Questionnaire.
CONCLUSIONS: The sole use of clinician-rated scales may underestimate prevalence of PD hallucinations, and there is room for introducing self- and informant-report tools. Nonetheless, clinician appraisals are critical in cases when informant and patient insight might be affected by the impact of illness on quality of life.

Entities:  

Keywords:  Parkinson's disease; informants; psychosis; self‐report; visual hallucinations

Year:  2018        PMID: 30637281      PMCID: PMC6277359          DOI: 10.1002/mdc3.12683

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  24 in total

1.  The malignant course of "benign hallucinations" in Parkinson disease.

Authors:  Christopher G Goetz; Wenqing Fan; Sue Leurgans; Bryan Bernard; Glenn T Stebbins
Journal:  Arch Neurol       Date:  2006-05

2.  Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis.

Authors:  I Arnulf; A M Bonnet; P Damier; B P Bejjani; D Seilhean; J P Derenne; Y Agid
Journal:  Neurology       Date:  2000-07-25       Impact factor: 9.910

3.  Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease.

Authors:  D Brandstaedter; S Spieker; G Ulm; U Siebert; T E Eichhorn; J C Krieg; W H Oertel; K Eggert
Journal:  J Neurol       Date:  2005-04-01       Impact factor: 4.849

4.  Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory.

Authors:  D I Kaufer; J L Cummings; P Ketchel; V Smith; A MacMillan; T Shelley; O L Lopez; S T DeKosky
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2000       Impact factor: 2.198

5.  Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

Authors:  D Aarsland; J P Larsen; E Tandberg; K Laake
Journal:  J Am Geriatr Soc       Date:  2000-08       Impact factor: 5.562

6.  Assessment of psychiatric complications in Parkinson's disease: The SCOPA-PC.

Authors:  Martine Visser; Dagmar Verbaan; Stephanie M van Rooden; Anne M Stiggelbout; Johan Marinus; Jacobus J van Hilten
Journal:  Mov Disord       Date:  2007-11-15       Impact factor: 10.338

7.  Executive functions are impaired in patients with Parkinson's disease with visual hallucinations.

Authors:  J Barnes; L Boubert
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-02       Impact factor: 10.154

8.  Neuropsychiatric problems in Parkinson's disease: comparisons between self and caregiver report.

Authors:  Audrey McKinlay; Randolph C Grace; John C Dalrymple-Alford; Timothy J Anderson; John Fink; Derek Roger
Journal:  Aging Ment Health       Date:  2008-09       Impact factor: 3.658

9.  Scales to assess psychosis in Parkinson's disease: Critique and recommendations.

Authors:  Hubert H Fernandez; Dag Aarsland; Gilles Fénelon; Joseph H Friedman; Laura Marsh; Alexander I Tröster; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Christopher G Goetz
Journal:  Mov Disord       Date:  2008-03-15       Impact factor: 10.338

10.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

Authors:  Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2008-11-15       Impact factor: 10.338

View more
  7 in total

1.  Neuropsychiatric Symptoms as a Reliable Phenomenology of Cerebellar Ataxia.

Authors:  Sharif I Kronemer; Mitchell B Slapik; Jessica R Pietrowski; Michael J Margron; Owen P Morgan; Catherine C Bakker; Liana S Rosenthal; Chiadi U Onyike; Cherie L Marvel
Journal:  Cerebellum       Date:  2020-09-30       Impact factor: 3.648

2.  Neuropsychiatric Symptoms Are Associated with Dementia in Parkinson's Disease but Not Predictive of it.

Authors:  Kyla-Louise Horne; Michael R MacAskill; Daniel J Myall; Leslie Livingston; Sophie Grenfell; Maddie J Pascoe; Bob Young; Reza Shoorangiz; Tracy R Melzer; Toni L Pitcher; Tim J Anderson; John C Dalrymple-Alford
Journal:  Mov Disord Clin Pract       Date:  2021-02-18

3.  Hallucinations in Older Adults: A Practical Review.

Authors:  Johanna C Badcock; Frank Larøi; Karina Kamp; India Kelsall-Foreman; Romola S Bucks; Michael Weinborn; Marieke Begemann; John-Paul Taylor; Daniel Collerton; John T O'Brien; Mohamad El Haj; Dominic Ffytche; Iris E Sommer
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

4.  Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice.

Authors:  Khashayar Dashtipour; Fiona Gupta; Robert A Hauser; Cherian A Karunapuzha; John C Morgan
Journal:  Parkinsons Dis       Date:  2021-01-04

Review 5.  Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations.

Authors:  Federico Rodriguez-Porcel; Kathryn A Wyman-Chick; Carla Abdelnour Ruiz; Jon B Toledo; Daniel Ferreira; Prabitha Urwyler; Rimona S Weil; Joseph Kane; Andrea Pilotto; Arvid Rongve; Bradley Boeve; John-Paul Taylor; Ian McKeith; Dag Aarsland; Simon J G Lewis
Journal:  Transl Neurodegener       Date:  2022-05-02       Impact factor: 9.883

6.  Participant and Study Partner Reported Impact of Cognition on Functional Activities in Parkinson's Disease.

Authors:  Brenna Cholerton; Kathleen L Poston; Lu Tian; Joseph F Quinn; Kathryn A Chung; Amie L Hiller; Shu-Ching Hu; Krista Specketer; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian
Journal:  Mov Disord Clin Pract       Date:  2019-12-14

7.  Contribution of neuropsychiatric symptoms in Parkinson's disease to different domains of caregiver burden.

Authors:  L M Chahine; R Feldman; A Althouse; B Torsney; L Alzyoud; S Mantri; B Edison; S Albert; M Daeschler; C Kopil; C Marras
Journal:  J Neurol       Date:  2021-02-25       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.